Jesper Lau, Ph.D.

Vice President, Protein and Peptide Chemistry at Novo Nordisk A/S

Agenda Sessions

• Discovery and Development of Semaglutide - The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

  Sep 16, 2:00pm

  View Session

• Chairperson's Remarks

  Sep 17, 8:20am

  View Session

Speakers at this event